Cytotoxicity of Liposomal Paclitaxel in Breast Cancer Cell Line MCF-7

Esfahani, Maedeh Koohi Moftakhari; Alavi, Seyed Ebrahim; Movahedi, Fatemeh; Alavi, Fatemeh; Akbarzadeh, Azim

doi:10.1007/s12291-013-0296-1

Cited by 21 publications

(14 citation statements)

References 12 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cispt-loaded liposome (LCispt) and PEGylated liposome (PLCispt) were successfully synthesized by the reverse-phase evaporation method, which has been extensively used for liposome synthesis [21,22]. In this study, cholesterol was used to enhance membrane packing and reduce membrane fluidity [23].…”

Section: Preparation Of Nanoparticlesmentioning

confidence: 99%

Enhanced Efficacy of PEGylated Liposomal Cisplatin: In Vitro and In Vivo Evaluation

Ghaferi

Asadollahzadeh

Akbarzadeh

et al. 2020

IJMS

View full text Add to dashboard Cite

This study aims to evaluate the potency of cisplatin (Cispt)-loaded liposome (LCispt) and PEGylated liposome (PLCispt) as therapeutic nanoformulations in the treatment of bladder cancer (BC). Cispt was loaded into liposomes using reverse-phase evaporation method, and the formulations were characterized using dynamic light scattering, scanning electron microscopy, dialysis membrane, and Fourier-transform infrared spectroscopy (FTIR) methods. The results showed that the particles were formed in spherical monodispersed shapes with a nanoscale size (221–274 nm) and controlled drug release profile. The cytotoxicity effects of LCispt and PLCispt were assessed in an in vitro environment, and the results demonstrated that PLCispt caused a 2.4- and 1.9-fold increase in the cytotoxicity effects of Cispt after 24 and 48 h, respectively. The therapeutic and toxicity effects of the formulations were also assessed on BC-bearing rats. The results showed that PLCispt caused a 4.8-fold increase in the drug efficacy (tumor volume of 11 ± 0.5 and 2.3 ± 0.1 mm3 in Cispt and PLCispt receiver rats, respectively) and a 3.3-fold decrease in the toxicity effects of the drug (bodyweight gains of 3% and 10% in Cispt and PLCispt receiver rats, respectively). The results of toxicity were also confirmed by histopathological studies. Overall, this study suggests that the PEGylation of LCispt is a promising approach to achieve a nanoformulation with enhanced anticancer effects and reduced toxicity compared to Cispt for the treatment of BC.

show abstract

Section: Preparation Of Nanoparticlesmentioning

confidence: 99%

Enhanced Efficacy of PEGylated Liposomal Cisplatin: In Vitro and In Vivo Evaluation

Ghaferi

Asadollahzadeh

Akbarzadeh

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…And it showed that not only the stability and residence time in plasma increased, but also the release rate reduced under physiological condition. [30][31][32] Particle size is a key parameter determining the cellular uptake of the nanoscale formulations. It was proved that particles and droplets could leak into the surrounding tumor tissue by pinocytosis in the range of 10-100 nm, yet be internalized by endocytosis within the range of 100 nm and 5 m. The size of nanoliposome is determined by the layers of phospholipid, less layers implying smaller particle size.…”

Section: Nanoliposomesmentioning

confidence: 99%

“…Esfahani et al 31 compared the toxicological e®ects of PTXloaded nanoliposomes and Taxol r in MCF-7 cells. The result showed that the nanoliposomal PTX formulation was more cytotoxic than Cremophor EL-based formulation.…”

Section: The Antitumor Activity Of Ptx-loaded Nanoliposomesmentioning

confidence: 99%

Nanoscale Drug Delivery Systems: A Current Review on the Promising Paclitaxel Formulations for Future Cancer Therapy

Fang

Yang

Wang

et al. 2015

NANO

View full text Add to dashboard Cite

Paclitaxel (PTX) is usual for the treatment of a variety of malignancies, however, its applications are greatly limited due to its poor water solubility. Over the past years, there has been a considerable research interest in the area of nanoscale drug delivery systems (DDSs) as carrier for PTX due to their solubilization, safety, targeting and controlled release. There are many di®erent types and shapes of nanoscale DDSs that have been prepared to deliver PTX, including nanoliposome, lipid nanoemulsion, nanosuspension, nanocapsule, nano¯ber, nanotube, nanopolymersome, micelle and nanoparticle (NP). Nanascale DDSs can be based on lipids, proteins, polysaccharides, polymers or other materials. The recent strategic developments of PTX formulation have been discussed with emphasis on lipid-, polymer-and protein-based nanoscale DDSs. Here we focus on the comparative analysis of the preparation, morphology, solubilization, targeting, penetrability, controllability and e±cacy pro¯le of various PTX-loaded nanoscale DDSs, which were reported in the di®erent researches. Meanwhile the advantages and disadvantages are also discussed for each type of DDS. Furthermore, the current review embodies an in-depth discussion of human serum albumin (HSA) NP formulation, which showed signi¯cantly great e±cacy and low toxicity. All the information obtained in this review might shed light on designing new and better nanoscale PTX formulations for potential anticancer applications in the clinic.

show abstract

“…Similarly, the cytotoxicity effect of nanoliposomal paclitaxel, an anti-breast cancer drug, is more than that of the standard form [96,97].…”

Section: Risks and Safety Issuesmentioning

confidence: 99%

Multidynamic Liposomes in Nanomedicine: Technology, Biology, Applications, and Disease Targeting

Ghosh

Ansar²

2014

Nanoparticles' Promises and Risks

View full text Add to dashboard Cite

Biocompatible and biodegradable liposome nanomedicine are finding large-scale application in delivery of drugs, RNA, antisense oligonucleotides, DNA, plasmids carrying gene, antioxidants to targeted sites for diagnosis, and treatment at cellular and molecular level of disease both in human and livestock.Conventional drug delivery system suffers from the disadvantage of narrow therapeutic index, poor serum solubility, and nonspecific target effects. Circumventing this problem, liposome drug nanoparticles are designed with the advantage of enhanced permeability, retention effect, selective targeted delivery, stimuli-induced release that can evade the host defense system, cross the bloodbrain barrier, thus conferring, synergetic effects, small interfering RNA (siRNA) co-delivery, multimodality therapies, and oral delivery of therapeutics at disease sites. Liposomes with diverse range of modifications are being designed to generate improvised medicine delivery systems. Immuno-liposomes, linked with antibodies are promising tools for targeted drug delivery to specific cancer cells. In the recent times several anti-cancer agents in nanodelivery systems are under preclinical and clinical studies. Lipid-based liposomal delivery systems of self-amplifying RNA vaccines are showing promising effects.Globally research is being carried out in generating liposomes with higher compatibility within the biological system in targeting a wide array of diseases including cancer, overcoming multidrug resistance, inflammatory diseases, thrombosis, psoriasis, muscular dystrophy, spinal cord injury, neurologic diseases, diabetes, parasite induced diseases, and cardiovascular diseases.

show abstract

Cytotoxicity of Liposomal Paclitaxel in Breast Cancer Cell Line MCF-7

Cited by 21 publications

References 12 publications

Enhanced Efficacy of PEGylated Liposomal Cisplatin: In Vitro and In Vivo Evaluation

Enhanced Efficacy of PEGylated Liposomal Cisplatin: In Vitro and In Vivo Evaluation

Nanoscale Drug Delivery Systems: A Current Review on the Promising Paclitaxel Formulations for Future Cancer Therapy

Multidynamic Liposomes in Nanomedicine: Technology, Biology, Applications, and Disease Targeting

Contact Info

Product

Resources

About